Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients

Bréchot, J.-M.; Chevret, Sylvie; Nataf, J; Gall, Catherine Le; Fretault, J.; Rochemaure, J; Chastang, C

doi:10.1016/s0959-8049(97)89010-7

Cited by 51 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As discussed earlier, keratin and keratin-related genes, i.e. CYFRA2.1, have been extensively documented as potential markers for lung cancer (Pastor et al, 1997;Brechot et al, 1997). Here we show that a variety of keratin related genes are upregulated in LSCC and the overall expression pro®les for these keratin genes are similar to that of L527S.…”

Section: Tissue-specific Genessupporting

confidence: 76%

“…Although several genes have been reported and tested as diagnostic and prognostic markers for lung cancer, i.e. carcinoembryonic antigen (CEA), urokinase plasminogen activator, squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (CYFRA 21..1) (Morita et al, 1998;Pastor et al, 1997;Brechot et al, 1997), and PGP 9.5 (Hibi et al, 1999), there is room for much improvement in this area.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis

et al. 2000

View full text Add to dashboard Cite

In order to develop eective vaccine products against human cancer, we are interested in identifying genes over-expressed in tumor cells. Through a combination of cDNA library subtraction and microarray technology, we identi®ed seventeen genes preferentially expressed in lung squamous cell carcinoma, including four novel genes. To date, expression pro®les of these genes were con®rmed by Northern and/or real-time analysis, and several genes were also found to be expressed in head and neck squamous tumors. Thus, these combined methods represent a high throughput approach for identifying tumor speci®c genes. Furthermore, the report of characterization on these genes will allow them to be exploited for their diagnostic, prognostic, and therapeutic potentials including immunotherapy and antibody based anticancer therapy. Oncogene (2000) 19, 1519 ± 1528.

show abstract

Section: Tissue-specific Genessupporting

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Previous studies have validated CYFRA 21-1 as a marker for monitoring disease in patients with various cancers, especially since CYFRA 21-1 concentrations and the sensitivity of CYFRA 21-1 increased progressively with clinical stage (Pujol et al, 1993;Sugama et al, 1994;Gaarenstroom et al, 1995;Takada et al, 1995;van der Gaast et al, 1995;Lai et al, 1996;Nakata et al, 1996;Brechot et al, 1997;Nisman et al, 1998;Brockmann et al, 2000;Doweck et al, 2000;Kawaguchi et al, 2000;Nakata et al, 2000) Our study also demonstrated that serum CYFRA 21-1 concentration was related to tumour stage of ICC, while serum CEA and CA 19-9 concentrations were not. CYFRA 21-1 concentrations differed according to the tumour size and vascular invasion, but not according to the number of tumours or nodal status.…”

Section: Cyfra 21-1 and Pathologic Variables In Patients With Iccmentioning

confidence: 99%

“…The CYFRA 21-1 assay was developed to measure a soluble fragment of cytokeratin 19 in serum. In non-small-cell lung cancer, CYFRA 21-1 was found to be significantly more sensitive than established markers, and this test may be a useful adjunct in clinical monitoring during and following treatment (Pujol et al, 1993;Stieber et al, 1993;Sugama et al, 1994;van der Gaast et al, 1994;Takada et al, 1995;Lai et al, 1996;Brechot et al, 1997;Nisman et al, 1998). In addition to lung cancer, CYFRA 21-1 has been reported to be a useful marker for cervical carcinoma (Gaarenstroom et al, 1995;Doweck et al, 2000), oesophageal cancer (Brockmann et al, 2000;Kawaguchi et al, 2000), breast cancer (Nakata et al, 2000), gastric cancer (Nakata et al, 1996), and bladder cancer - (Sanchez-Carbayo et al, 1999).…”

mentioning

confidence: 99%

Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer

et al. 2003

View full text Add to dashboard Cite

Using an electrochemiluminescence immunoassay, CYFRA 21-1 concentrations were measured in sera from 187 patients with primary liver cancer (164 with hepatocellular carcinoma (HCC) and 23 with intrahepatic cholangiocarcinoma (ICC)) and 87 patients with benign liver diseases. Concentrations of CYFRA 21-1 were significantly higher in patients with ICC (5.0; interquartile range 3.1 -10.7 ng ml À1 ) than in those with benign liver disease (1.4; 1.0 -1.9; Mann -Whitney U-test, Po0.0001) or HCC (1.7; 1.1 -2.7; MannWhitney U-test, Po0.0001). Using cutoff values selected for 95% specificity in the benign group (3.0 ng ml À1 ), CYFRA 21-1 showed higher sensitivity for ICC (87.0%) than three commonly used markers including a-fetoprotein (17.4%), carcinoembryonic antigen (34.8%), and carbohydrate antigen 19-9 (60.9%). Serum CYFRA 21-1 increased in ICC from stages I/II to IV (Kruskal -Wallis test, P ¼ 0.0102). CYFRA 21-1 concentration increased with extent of local invasion, but not nodal status. Serum CYFRA 21-1 represents a useful diagnostic test for ICC that offers high sensitivity. CYFRA 21-1 reflected differences in tumour burden, suggesting applicability to staging and follow-up.

show abstract

“…The prognostic value of CYFRA 21-1 (a fragment of cytokeratin subunit 19) in this disease has been suggested (Pujol et al, 1993;Wieskopf et al, 1995;Brechot et al, 1997). NSE, the γ-subunit of enolase, has been widely investigated as a marker of small cell lung cancer (SCLC; Jorgensen et al, 1989).…”

mentioning

confidence: 99%

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors

et al. 2001

View full text Add to dashboard Cite

Patients with lung cancer frequently suffer from brain metastases at the time of presentation. This condition affects approximately 10% of non-small cell lung cancer (NSCLC) patients (Newman and Hansen, 1974;Sorensen et al, 1988). Surgery is feasible only for a small proportion of these patients. Whole brain radiotherapy has been, hitherto, the generally recommended treatment in inoperable patients. The survival of NSCLC patients with brain metastases is poor, reported to be between 3 to 6 months in patients treated with medical therapies, either radiotherapy or chemotherapy (compared to 6-10 months in other advanced NSCLC (Paesmans et al, 1995;Shepherd, 1999)). Furthermore, brain metastases at the time of presentation of lung cancer seems to be a worse prognosis (Sorensen et al, 1988) than metachronous brain metastases.New therapeutic strategies are needed to improve the outcome of these patients. The knowledge of prognostic determinants might be important in both clinical trials and routine practice (Komaki et al, 1993;Charloux et al, 1997;Paesmans et al, 1997;Merrill et al, 1999). In the former setting, prognostic co-variables must be taken into account in survival analyses; by way of illustration, in a given randomized trial, the statement that a difference in survival is related to the effects of the treatment must be supported by a proportional hazards model demonstrating that this effect does not depend on well-known prognostic determinants (Depierre et al, 1999;Furuse et al, 1999). In the second setting, a therapeutic decision might be influenced by the state of prognostic variables (Komaki et al, 1993).Here we especially take a look at the prognostic significance of 2 specific serum markers, CYFRA 21-1 and neuron-specific enolase (NSE). The prognostic value of CYFRA 21-1 (a fragment of cytokeratin subunit 19) in this disease has been suggested (Pujol et al, 1993;Wieskopf et al, 1995;Brechot et al, 1997). NSE, the γ-subunit of enolase, has been widely investigated as a marker of small cell lung cancer (SCLC;Jorgensen et al, 1989). Although only a small proportion of NSCLC presented with a high NSE level, this marker might indirectly reflect; i) a neuroendocrine component of the disease in favour of tumour heterogeneity; ii) a Summary A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pretherapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The accrual period was January 1991 to December 1998. Prognosis was analysed using both univariate and multivariate (Cox model) statistics. The median survival of the whole population was 28 weeks. Univariate analysis (log-rank), showed that patients affected by one of the following characteristics proved to have a shorter survival in comparison with the opposite status...

show abstract

Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients

Cited by 51 publications

References 16 publications

Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis

Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis

Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors

Contact Info

Product

Resources

About